Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Weight change and blood coagulability and fibrinolysis in healthy obese women

International Journal of Obesity volume 25, pages 212–218 (2001)Cite this article

Abstract

OBJECTIVES: To study the effect of weight loss and subsequent weight maintenance or weight regain on the activities of FVII and plasminogen activator inhibitor 1 (PAI-1) and the concentration of fibrinogen over 12 months in obese women consuming a hypoenergetic, low-fat diet with or without orlistat. In addition, the relation between the changes of the activities of PAI-1 and FVII with the changes of other cardiovascular risk factors were examined.

METHODS AND PROCEDURES: Design—a 12-month randomized double-blind weight reduction trial of placebo and orlistat. Subjects—51 healthy obese women (age 44±0.7 y, BMI 36.2±0.5 kg/m2, mean±s.e.m.) Treatment—the participants were on a hypoenergetic diet (–600 kcal daily). The diet was adjusted for actual body weight (–300 kcal) at 6 months. Women were randomized to receive either orlistat 120 mg three times daily (n=25) or placebo three times daily (n=26) for 12 months according to a double-blind protocol after a 1 month run-in period. Measurements—changes of body weight, body composition, haemostatic and other cardiovascular risk factors were measured at 3–6 month intervals. The activity of plasma PAI-1 was measured by a chromogenic method, fibrinogen by the PT-derived method and the activity of FVII by the one-stage method.

RESULTS: The changes in body weight between orlistat and placebo groups were not statistically significantly different. Orlistat did not influence haemostatic factors beyond its effect on weight loss. Therefore, the results of the orlistat and placebo groups were pooled. The average weight loss at 3, 6 and 12 months was 7.6, 9.5 and 10.0 kg, respectively (P<0.001). Between 6 and 12 months, 35% of women regained weight, 24% had stable weight and 41% continued to lose weight. No changes in the mean plasma fibrinogen concentration were observed at any time point during the trial. During the first 3 months the activities of PAI-1 and FVII decreased. The decline depended on the magnitude of weight loss. Between months 6 and 12 the changes of PAI-1 and FVII activities paralleled the changes of body weight. The activities rose with weight rebound but remained below the 6-month values if weight loss was sustained or continued. The changes of serum insulin were significantly correlated with the changes of both PAI-1 and FVII at 6 months and with PAI-1 at 12 months.

CONCLUSIONS: The maintenance of modest weight loss is associated with long-term benefits in PAI-1 and FVII in obese women. The change of serum insulin is associated with the changes of PAI-1 activities. Fibrinogen is not affected by modest weight loss.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankins SE, Hennekens CH, Speizer FE . Body weight and mortality among women New Engl J Med 1995 333: 677–685.

    Article  CAS  Google Scholar 

  2. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC . Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men Am J Epidemiol 1995 141: 1117–1127.

    Article  CAS  Google Scholar 

  3. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y . Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations Br Med J 1979 1: 153–156.

    Article  CAS  Google Scholar 

  4. Balleisen L, Bailey J, Epping P-H, Schulte H, van de Loo J . Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using and menopause Thromb Haemostasis 1985 54: 475–479.

    CAS  Google Scholar 

  5. Sundell IB, Nilsson TK, Hallmans G, Nygren C . The effect of body build, diet and endocrine factors on the extrinsic fibrinolytic system in healthy young women Scand J Clin Lab Invest 1988 48: 557–564.

    Article  CAS  Google Scholar 

  6. Baron JA, Mann J, Stukel T . Effect of weight loss on coagulation factors VII and X Am J Cardiol 1989 64: 519–522.

    Article  CAS  Google Scholar 

  7. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK . Impact of weight loss on plasminogen activator inhibitor (PAI-1), Factor VII, and other hemostatic factors in moderately overweight adults Arterioscl Thromb 1993 13: 162–169.

    Article  CAS  Google Scholar 

  8. Svendsen OL, Hassager C, Christiansen C, Nielsen JD, Winther K . Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen. Effect of dieting with or without exercise in overweight postmenopausal women Arterioscler Thromb Vasc Biol 1996 16: 381–385.

    Article  CAS  Google Scholar 

  9. Leenen R, Kooy KVD, Meyboom S, Seidell JC, Deurenberg P . Relative effects of weight loss and dietary fat modification on serum lipid levels in the dietary treatment of obesity J Lipid Res 1993 34: 2183–2191.

    CAS  PubMed  Google Scholar 

  10. Andersen P, Selfeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, Birkeland K . Increased insulin sensitivity in obese women with polycystic ovary syndrome Metabolism 1995 44: 611–616.

    Article  CAS  Google Scholar 

  11. Marckmann P, Tourbo S, Astrup A . Sustained improvement in blood lipids, coagulation and fibrinolysis after major weight loss in obese subjects Eur J Clin Nutr 1998 52: 329–333.

    Article  CAS  Google Scholar 

  12. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H, Krempf M . Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients Lancet 1998 352: 167–172.

    Article  Google Scholar 

  13. Rossi E, Mondonico P, Lombardi A, Preda L . Method for the determination of functional (clottable) fibrinogen by the new family of ACL coagulometers Thromb Res 1988 52: 453–468.

    Article  CAS  Google Scholar 

  14. Wahlefeld AW . Triglycerides determination after enzymatic hydrolysis. In: Bergmeyer H, Gawehn K (eds) Methods of Enzymatic Analysis Chemie: Weinheim 1974 1831–1835.

    Chapter  Google Scholar 

  15. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW . Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency Clin Chem 1983 29: 1075–1080.

    CAS  PubMed  Google Scholar 

  16. Van Gaal LF, Wauters MA, De Leeuw IH . The beneficial effects of modest weight loss on cardiovascular risk factors Int J Obes Relat Metab Disord 1997 21 (Suppl 1): S5–S9.

    Google Scholar 

  17. Primrose JN, Davies JA, Prentice CRM, Hughes R, Johnston D . Reduction in Factor VII, fibrinogen and plasminogen activator inhibitor-1 after surgical treatment of obesity Thromb Haemostasis 1992 68: 396–399.

    Article  CAS  Google Scholar 

  18. Hankey CR, Rumley A, Lowe GDO, Woodward M, Lean MEJ . Moderate weight reduction improves red cell aggregation and factor VII activity in overweight subjects Int J Obes Relat Metab Dis 1997 21: 644–650.

    Article  CAS  Google Scholar 

  19. Kockx M, Leenen R, Seidell J, Princen HMG, Kooistra T . Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss Thromb Haemostasis 1999 82: 1490–1496.

    Article  CAS  Google Scholar 

  20. Marvri A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, Binder BR . Impact of adipose tissue on plasma plaminogen activator inhibitor-1 in dieting obese women Arterioscler Thromb Vasc Biol 1999 19: 1582–1587.

    Article  Google Scholar 

  21. Eliasson M, Asplund K, Evrin P-E, Lindahl B, Lundblad D . Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study Metabolism 1994 43: 1579–1586.

    Article  CAS  Google Scholar 

  22. Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D . Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2 Thromb Haemostasis 1988 60: 491–494.

    Article  CAS  Google Scholar 

  23. Schneider DJ, Nordt TK, Sobel BE . Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells Diabetes 1992 41: 890–895.

    Article  CAS  Google Scholar 

  24. Stiko-Rahm A, Wiman B, Hamsten A, Nilson J . Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells induced by very low density lipoprotein Arteriosclerosis 1990 10: 1067–1073.

    Article  CAS  Google Scholar 

  25. Haffner SM, Agostino RD, Mykkänen L, Hales CN, Savage PJ, Bergman RN, O'Leary D, Rewers M, Selby J, Tracy R, Saad MF . Proinsulin and insulin concentrations in relation to carotid wall thickness. Insulin resistance atherosclerosis study Stroke 1998 29: 1498–1503.

    Article  CAS  Google Scholar 

  26. Nordt TK, Sawa H, Satoshi F, Bode C, Sobel BE . Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo J Mol Cell Cardiol 1998 30: 1535–1545.

    Article  CAS  Google Scholar 

  27. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE . The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance Metabolism 1993 43: 945–949.

    Article  Google Scholar 

  28. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H . Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old-men Thromb Vasc Biol 1998 18: 258–264.

    Article  CAS  Google Scholar 

  29. Vuorinen-Markkola H, Puhakainen I, Yki-Järvinen H . No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man Thromb Haemostasis 1992 67: 117–120.

    Article  CAS  Google Scholar 

  30. Mykkänen L, Rönnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M . Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity Arterioscler Thromb 1994 14: 1264–1271.

    Article  Google Scholar 

  31. Nagi DK, Tracy R, Pratley R . Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians Metabolism 1996 45: 1243–1247.

    Article  CAS  Google Scholar 

  32. Fendri S, Roussel B, Lormeau B, Tribout B, Lalau JD . Insulin sensitivity, inusln action and fibrinolysis activtiy in nondiabetic obese subjects Metabolism 1998 47: 1372–1375.

    Article  CAS  Google Scholar 

  33. Wing RR, Jeffery RW . Effects of modest weight loss on changes in cardiovascular risk factors: are there differences between men and women or between weight loss and maintenance Int J Obes Relat Metab Disord 1995 19: 67–73.

    CAS  Google Scholar 

  34. Landsberg L . Insulin and the sympathetic nervous system in the pathophysiology of hypertension Blood Pressure 1996 1 (Suppl 1): 25–29.

    CAS  PubMed  Google Scholar 

  35. Jung JB, Shetty PS, Barrand M, Callingham BA, James WPT . Role of catecholamines in hypotensive response to dieting Br Med J 1978 1: 12–13.

    Article  Google Scholar 

  36. Landsberg L, Young JB . Fasting, feeding and regulation of the sympathetic nervous system New Engl J Med 1978 298: 1295–1300.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by a research grant from F Hoffmann-La Roche Ltd and the Yrjö Jahnsson Foundation.

Author information

Authors and Affiliations

  1. Department of Clinical Nutrition, University of Kuopio, Kuopio, Finland

    P Rissanen & M Uusitupa

  2. Department of Haemostasis, Finnish Red Cross Blood Transfusion Service of Helsinki, Finland

    E Vahtera & T Krusius

  3. Obesity Research Unit, Helsinki University Central Hospital, Helsinki, Finland

    P Rissanen & A Rissanen

  4. Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland

    A Rissanen

Authors
  1. P Rissanen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Vahtera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Krusius
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Uusitupa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Rissanen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Rissanen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rissanen, P., Vahtera, E., Krusius, T. et al. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes 25, 212–218 (2001). https://doi.org/10.1038/sj.ijo.0801540

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0801540

Keywords

This article is cited by

Search

Advanced search

Quick links